AI pioneer Innoplexus and phytopharmaceutical company DrD are partnering toRead More
Partnering to unlock the true potential of cannabis in medical care
Category: featured
Innoplexus and Inflection Biosciences enter strategic collaboration based on Artificial Intelligence
Innoplexus and Inflection Biosciences enter strategic collaboration based on Artificial Intelligence to expedite PIM kinase inhibitor development ESCHBORN, Germany, May 30, 2022 – Innoplexus, a global leader in AI-based drug discovery and development, and Inflection Biosciences Ltd., an innovative biotechnology company focused upon developing innovative small molecule therapeutics for the treatment of cancer, autoimmune and …
Parexel and Innoplexus Unveil Single Source of COVID-19 Information for Researchers, Sponsors and Patients During the Pandemic
COVID-19 Clearinghouse enables direct access to latest COVID-19 datasets, publications, research and clinical trials BOSTON and DURHAM, N.C. and ESCHBORN, Germany, Sept. 24, 2020 (GLOBE NEWSWIRE) — Parexel, a leading provider of solutions to accelerate the development and delivery of innovative new therapies to market to improve world health, from Clinical through Commercialization, in collaboration …
New app for cancer patients
Das Eschborner Unternehmen Innoplexus hat eine neue App namens „Curia“ für Krebspatienten veröffentlicht. Mit dem Computerprogramm, das sich unentgeltlich herunterladen lässt, finden Patienten Informationen zu Behandlungsmöglichkeiten, die Namen von Fachleuten in Deutschland und klinische Studien aus der ganzen Welt. Die App leitet den Nutzer Schritt für Schritt durch einen Fragebogen, mit dem die wichtigsten Diagnosemerkmale …
Innoplexus wins Silver Edison Award for OntosightⓇ Explore
Frankfurt, Germany, March 26, 2020 — Innoplexus AG has been honored with the Silver Edison Award 2020 for its proprietary OntosightⓇ Explore platform. The recognition comes in the category of Artificial Intelligence & User Experience. The finalists of the Edison Awards were announced on February 11th, 2020. OntosightⓇ Explore is a specialized life science based AI-based platform …
Innoplexus wins Silver Edison Award for OntosightⓇ Explore Read More »
AI CTP engine estimated failure for Biogen’s aducanumab
While drug development can be incredibly lucrative, it is a very risky business. German company Innoplexus has developed a domain-specific AI prediction engine, which recently caught attention by correctly predicting that Biogen’s Alzheimer’s drug aducanumab would fail with 70% to 90% certainty. Allie Nawrat finds out more. In March 2019, Biogen’s long anticipated drug for …
AI CTP engine estimated failure for Biogen’s aducanumab Read More »
How can AI be leveraged for Clinical Trial Prediction?
Successful clinical trials occur at a ratio of 1 in 10, costing around $2-$3 billion, with drugs taking 10–12 years to be approved. High costs, 90% failure rate, and the lengthy timeline have all contributed to Pharma’s incompetence. The technique of using multiple compounds in the trial phase to increase the chances of drug approval …
How can AI be leveraged for Clinical Trial Prediction? Read More »
Innoplexus launches new Blockchain platform for Pharma innovation
If your loved one was diagnosed with a potentially fatal illness, wouldn’t you want all the information possible to be available to those who could formulate a targeted treatment? Of course you would. And that’s precisely what inspired Gunjan Bhardwaj to found Innoplexus, with the aim of bringing more sophisticated machine learning and AI to …
Innoplexus launches new Blockchain platform for Pharma innovation Read More »
Innoplexus signs MoU to provide academic license for its iPlexus platform to Regional Cancer Centre, Gwalior, India
Innoplexus is proud to announce our collaboration with the Regional Cancer Centre, Gwalior. Innoplexus has executed an MoU to provide an academic license for its iPlexus platform to RCC, Gwalior, India. The academic license allows doctors and researchers with free access to iPlexus. Doctors and researchers will be able to gain insights into the latest …
